Wheal characteristics in chronic spontaneous urticaria and their association with omalizumab response
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Omalizumab is one of the recommended add-on biologic therapies for chronic spontaneous urticaria (CSU) refractory to antihistamines. Although clinical heterogeneity in wheal appearance is frequently observed, its association with treatment response remains unclear. Objective To determine whether wheal appearance is associated with omalizumab response in CSU patients. Methods Patients with CSU who received omalizumab were retrospectively enrolled. Demographic characteristics, laboratory parameters, and detailed wheal characteristics were collected before treatment initiation. Wheal characteristics were systematically categorized according to color, morphology, density, and predominant site. Treatment response was assessed longitudinally, and patients were stratified according to response kinetics into early responders, late responders, and non-responders. Multivariable logistic regression and several feature selection methods, including Boruta, mRMR, RFE, and LASSO, were applied to identify candidate response-associated variables. Four machine learning (ML) algorithms, including random forest, XGBoost, SVM, and LightGBM, were developed and compared. Model interpretability was assessed using SHAP. Results A total of 119 omalizumab-naive CSU patients were included. Wheal characteristics (color, morphology, density, and predominant site) were not independently associated with treatment response in multivariable logistic regression analyses. Among the ML models, RFE-XGBoost model achieved the highest AUC (0.870, 95% CI 0.719–0.972). Dermatology Life Quality Index (DLQI), Urticaria Activity Score over 7 days (UAS7), and baseline level of total IgE were the most influential response-associated variables. Wheal characteristics showed limited contribution to model performance. Conclusion Routinely assessed wheal characteristics were not found to have an independent association with omalizumab response in CSU and showed limited incremental value over DLQI, UAS7, and total IgE.
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,508
Awards: G5674686441, G7736380927
OpenAlex ID: W7225991877
